Inclusion Criteria:

          1. Dose Escalation Phase:

             Patients must be refractory to, or intolerant of, existing therapies known to provide
             clinical benefit for their condition (i.e., cancer diagnosis)

             Dose Expansion Phase:

             Ovarian:

             Patients with confirmed diagnosis of unresectable epithelial ovarian, fallopian tube,
             or primary peritoneal cancer must have received ≤ 3 prior lines of therapy in a
             platinum resistant setting. BRCA mutant patients are excluded unless they have failed
             previous line with a PARP inhibitor

             Pancreatic:

             Patients with confirmed diagnosis of pancreatic cancer must have received ≤2 prior
             lines of therapy

             Triple Negative Breast Cancer:

             Patients with confirmed diagnosis of metastatic TNBC must have received ≤ 3 prior
             lines of therapy for metastatic disease

             Glioblastoma:

             Patients with confirmed relapsed or refractory glioblastoma must have received ≤2
             prior lines of systemic therapy

             CD36-high basket cohort:

             Patients with solid tumor cancers that have high expression of CD36 by
             immunohistochemistry. Patients must have received ≤ 3 prior lines of therapy for
             metastatic disease

          2. Patient has evaluable disease by RECIST v1.1

          3. Patient has a performance status (PS) of 0-2 on the Eastern Cooperative Oncology Group
             (ECOG) scale

          4. Patient is at least 21 days (12 weeks for glioblastoma patients) removed from
             therapeutic radiation or chemotherapy prior to the first scheduled day of dosing with
             VT1021

          5. Patient has adequate organ function

          6. Patient agrees to use acceptable methods of contraception during the study and 60 days
             after the last dose of VT1021

        Exclusion Criteria:

          1. Diagnosis of another malignancy within the past 2 years (excluding a history of
             carcinoma in situ of the cervix, superficial non-melanoma skin cancer, superficial
             bladder cancer, or endometrial cancer that has been adequately treated, or stage 1
             prostate cancer that does not require treatment)

          2. History of a major surgical procedure or a significant traumatic injury within 14 days
             prior to commencing treatment, or the anticipation of the need for a major surgical
             procedure during the course of the study

          3. Treatment with investigational therapy(ies) within 5 half-lives of the investigational
             therapy prior to the first scheduled day of dosing with VT1021, or 4 weeks if the
             half-life of the investigational agent is not known

          4. Concurrent serious (as determined by the Principal Investigator) medical conditions,
             including, but not limited to, New York Heart Association (NYHA) class III or IV
             congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled
             infection, active hepatitis B, hepatitis C or HIV, or other significant co-morbid
             conditions that, in the opinion of the Investigator, would impair study participation
             or cooperation

          5. Pregnancy or lactation

          6. Evidence of symptomatic brain metastases. Patients with treated (surgically excised or
             irradiated) and stable brain metastases are eligible, assuming the patient has
             adequately recovered from treatment

          7. Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy

          8. Requirement to palliative radiotherapy to lesions that are defined as target lesions
             by RECIST criteria at the time of study entry